Trending...
- New Climate Thriller Explores Corporate Control of Weather in "The Rainmakers"
- Australian Aboriginal Cultural Immersions and First Nations Workshops
- Tacoma: At-Large City Council Member Olgy Diaz Hosts 'Bridging the Gap: Local Solutions in the Federal Landscape' on December 6
SEATTLE, March 31, 2021 /PRNewswire/ -- OpenTreatments Foundation, a nonprofit organization with a mission to enable treatments for rare genetic diseases regardless of rarity and geography, today announced the launch of OpenTreatments, an innovative open source software platform that will enable patients to create gene therapies for rare genetic diseases. The platform enables patient-led organizations to develop treatments using the Adeno Associated Virus (AAV) gene therapy technology. It provides a robust roadmap, advice from drug development experts, and research infrastructure (labs, contract research facilities, manufacturing facilities, software tools) to execute every step of the drug development pipeline from planning, design, manufacturing, all the way to clinical trials.
"Rare disease drug development is a complex maze. OpenTreatments software platform empowers patient-led organizations to navigate that maze and create treatments for the diseases they care about. We will enable the hand off of these therapies to commercial, governmental and philanthropic entities to ensure patients get access to the therapies for the years to come", said Sanath Kumar Ramesh, founder and CEO of the OpenTreatments Foundation.
The Linux Foundation, a nonprofit organization enabling mass innovation through open source, is collaborating with OpenTreatments Foundation through RareCamp software project to provide open governance and source code for OpenTreatments platform.
More on Washingtoner
There are 400 million patients worldwide affected by more than 7,000 rare diseases, yet treatments for rare genetic diseases are an underserved area. More than 95 percent of rare diseases do not have an approved treatment, and new treatments are estimated to cost more than $1 billion. "Recently, patient groups have risen as the primary driving force behind drug development for rare diseases. The support provided by OpenTreatments to patient-led organizations will dramatically reduce both the time and cost of drug development, leading to more treatments reaching patients faster.", said Dr. Ashley Winslow, Chief Scientific Officer of Odylia Therapeutics, a non-profit organization working to bring treatments to rare diseases and a collaborator of OpenTreatments Foundation.
OpenTreatments Foundation is a collaborative effort with patients, advocacy and industry organizations. Baylor College of Medicine, Castle IRB, Charles River, Columbus Children's Foundation, GlobalGenes, Odylia Therapeutics, RARE-X, and Turing.com are collaborating with OpenTreatments Foundation to support patient-led organizations with drug development advice and research infrastructure necessary to advance their treatments. Amazon Web Services (AWS) is providing expert advice and support to develop and run the OpenTreatments software platform on the AWS cloud. OpenTreatments Foundation's leadership includes patients and rare disease drug development experts Julia Vitarello, Dr. Plavi Mittal, and Dr. Ethan Perlstein as board of directors and Sanath Kumar Ramesh as the Founder and CEO.
More on Washingtoner
OpenTreatments software platform is launching with three pilot gene therapy programs from patient-led organizations CureCMD, IDefine and CureGPX4. "OpenTreatments will enable IDefine to accelerate our mission by distilling down the necessary steps in the development of a gene therapy program into a concise and approachable plan", said Geoff Rhyne, Co-Founder and CEO of IDefine, a patient-led organization tackling Kleefstra Syndrome caused by mutations in EHMT1 gene.
Patient-led organizations with an interest in building gene therapy can apply to join the platform at OpenTreatments.org.
About OpenTreatments Foundation
OpenTreatments Foundation's mission is to enable treatments for all genetic diseases regardless of rarity and geography. Through the OpenTreatments software platform, patient-led organizations get access to a robust roadmap, people, and infrastructure necessary to build a gene therapy program. The software platform offers project management capabilities to manage the program while reducing time and money necessary for the development. For more information, please visit: OpenTreatments.org.
Media Contact
Jennifer Cloer
for the OpenTreatements Foundation
and Linux Foundation
503-867-2304
[email protected]
SOURCE OpenTreatments Foundation
"Rare disease drug development is a complex maze. OpenTreatments software platform empowers patient-led organizations to navigate that maze and create treatments for the diseases they care about. We will enable the hand off of these therapies to commercial, governmental and philanthropic entities to ensure patients get access to the therapies for the years to come", said Sanath Kumar Ramesh, founder and CEO of the OpenTreatments Foundation.
The Linux Foundation, a nonprofit organization enabling mass innovation through open source, is collaborating with OpenTreatments Foundation through RareCamp software project to provide open governance and source code for OpenTreatments platform.
More on Washingtoner
- 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
- FlintLab Announces Strategic Partnership with Genymotion
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- West Coast Hospitality Assumes Management of The Dundee Hotel
- Spokane: Council Member Paul Dillon Honored with Legislative Champion Award by We Train Washington
There are 400 million patients worldwide affected by more than 7,000 rare diseases, yet treatments for rare genetic diseases are an underserved area. More than 95 percent of rare diseases do not have an approved treatment, and new treatments are estimated to cost more than $1 billion. "Recently, patient groups have risen as the primary driving force behind drug development for rare diseases. The support provided by OpenTreatments to patient-led organizations will dramatically reduce both the time and cost of drug development, leading to more treatments reaching patients faster.", said Dr. Ashley Winslow, Chief Scientific Officer of Odylia Therapeutics, a non-profit organization working to bring treatments to rare diseases and a collaborator of OpenTreatments Foundation.
OpenTreatments Foundation is a collaborative effort with patients, advocacy and industry organizations. Baylor College of Medicine, Castle IRB, Charles River, Columbus Children's Foundation, GlobalGenes, Odylia Therapeutics, RARE-X, and Turing.com are collaborating with OpenTreatments Foundation to support patient-led organizations with drug development advice and research infrastructure necessary to advance their treatments. Amazon Web Services (AWS) is providing expert advice and support to develop and run the OpenTreatments software platform on the AWS cloud. OpenTreatments Foundation's leadership includes patients and rare disease drug development experts Julia Vitarello, Dr. Plavi Mittal, and Dr. Ethan Perlstein as board of directors and Sanath Kumar Ramesh as the Founder and CEO.
More on Washingtoner
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- Everett Chamber and Herald Launch 2026 Business Directory Reaching 30,000 Local Households
OpenTreatments software platform is launching with three pilot gene therapy programs from patient-led organizations CureCMD, IDefine and CureGPX4. "OpenTreatments will enable IDefine to accelerate our mission by distilling down the necessary steps in the development of a gene therapy program into a concise and approachable plan", said Geoff Rhyne, Co-Founder and CEO of IDefine, a patient-led organization tackling Kleefstra Syndrome caused by mutations in EHMT1 gene.
Patient-led organizations with an interest in building gene therapy can apply to join the platform at OpenTreatments.org.
About OpenTreatments Foundation
OpenTreatments Foundation's mission is to enable treatments for all genetic diseases regardless of rarity and geography. Through the OpenTreatments software platform, patient-led organizations get access to a robust roadmap, people, and infrastructure necessary to build a gene therapy program. The software platform offers project management capabilities to manage the program while reducing time and money necessary for the development. For more information, please visit: OpenTreatments.org.
Media Contact
Jennifer Cloer
for the OpenTreatements Foundation
and Linux Foundation
503-867-2304
[email protected]
SOURCE OpenTreatments Foundation
Filed Under: Business
0 Comments
Latest on Washingtoner
- Tacoma City Council Approves Tideflats Subarea Plan
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- Boeing–Airbus Accreditation Breakdown: How "Probably" Certificates Created Worldwide Risk
- Spokane: Suspect in Custody After Shooting Leaves One Subject Deceased
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- Spokane: Funding Available for Culturally Specific Treatment of Opioid Use Disorder Grants
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- BEC Technologies Expands MX-220 5G Industrial Router Series for Edge Connectivity
- "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
- Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
- Fenix Consulting Group Expands Orange County Office to Meet Growing Client Demand
- Signature Smiles Dental Group Unveils New User-Friendly Website
- CCHR: New Data Shows Millions of U.S. Children Caught in Escalating Psychiatric Polypharmacy
- QwickContractReview.com Launches $19 Contract Review Service to Protect Consumers from Hidden Contract Risks
- Tacoma: At-Large City Council Member Olgy Diaz Hosts 'Bridging the Gap: Local Solutions in the Federal Landscape' on December 6
- Spokane: New Ordinance Seeks to Prohibit Sale, Distribution of Kratom
- 100% Bonus Depreciation Places New Spotlight on Off The Hook Yacht Sales Inc. (N Y S E: OTH) as a Major Player in the $57 Billion U.S. Marine Market
- CNCPW Benchmarks Global Industry Standards: Integrating SEC Compliance with 3 Million TPS Architecture for Institutional Infrastructure